Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002480006 | SCV004805874 | uncertain significance | Telangiectasia, hereditary hemorrhagic, type 1 | 2024-03-15 | reviewed by expert panel | curation | The NM_001114753.3: c.1711C>T variant in ENG is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 571 (p.Arg571Cys). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0004233 (15/35434 alleles) in the Admixed American population. The computational predictor REVEL gives a score of 0.31, which is neither above nor below the thresholds predicting a damaging or benign impact on ENG function. In summary, this variant meets the criteria to be classified as a variant of uncertain significance for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: None (specification version 1.0.0; 1/4/2024). |
Eurofins Ntd Llc |
RCV000725125 | SCV000334293 | uncertain significance | not provided | 2015-09-17 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000403112 | SCV000539101 | uncertain significance | not specified | 2016-06-23 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Variant reported in 1 proband with juvenile polyposis |
Labcorp Genetics |
RCV001053352 | SCV001217610 | likely benign | Hereditary hemorrhagic telangiectasia | 2024-09-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002480006 | SCV002782117 | uncertain significance | Telangiectasia, hereditary hemorrhagic, type 1 | 2021-11-24 | criteria provided, single submitter | clinical testing |